A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)
Trial details
- Registry ID
- NCT06431893
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as OT-058; OT-58; TVT-058
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)NCT06431893 | TVTX | Phase 3 | Enrolling by invitation | 2030-08Estimated |
| Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentNCT06247085 | TVTX | Phase 3 | Recruiting | 2027-08Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |